Viridian Therapeutics (NASDAQ:VRDN) Stock Price Target Raised at Leerink Partners

Viridian Therapeutics (NASDAQ:VRDN) had its price objective increased by Leerink Partners from $50.00 to $54.00 in a report issued on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts also recently weighed in on the company. Wells Fargo & Company boosted their price target on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. HC Wainwright lifted their target price on Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Needham & Company LLC lifted their target price on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wedbush upped their target price on Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Viridian Therapeutics Trading Down 1.8%

NASDAQ VRDN opened at $28.55 on Thursday. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a fifty day simple moving average of $21.88 and a two-hundred day simple moving average of $21.83. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a market cap of $3.23 billion, a P/E ratio of -7.43 and a beta of 1.07.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. The firm had revenue of $25.75 million for the quarter, compared to analyst estimates of $4.72 million. On average, analysts forecast that Viridian Therapeutics will post -4.07 earnings per share for the current year.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC acquired a new position in Viridian Therapeutics in the second quarter valued at approximately $25,306,000. Rice Hall James & Associates LLC purchased a new stake in Viridian Therapeutics in the 2nd quarter worth approximately $21,601,000. Elmind Capital LP purchased a new stake in Viridian Therapeutics in the 2nd quarter worth approximately $18,093,182. Bank of America Corp DE acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth approximately $17,348,000. Finally, Deutsche Bank AG acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter worth approximately $8,870,000.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Multiple firms raised their price targets and maintained or initiated positive ratings. On Nov. 5, Leerink Partners lifted its target to $54 and RBC to $41, both with “outperform” ratings; Truist raised its target to $42 (“buy”), while Wells Fargo, Wedbush and HC Wainwright also increased targets. Leerink Partners rating
• Positive Sentiment: Viridian’s Q3 loss of $0.81 per share was narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million topped the $4.72 million consensus. The earnings beat may have helped support investor sentiment, although the per-share loss widened from $0.34 a year earlier. Q3 results
• Positive Sentiment: Viridian outlined commercial and pipeline milestones: Lumvoa’s launch is targeting broad coverage within six to nine months, and the company signaled a biologics license application for elegrobart in Q1 2027. Progress toward broader access and the regulatory filing could strengthen the growth outlook, though execution remains important. Lumvoa and elegrobart milestones
• Negative Sentiment: A separate valuation analysis argued VRDN could be overvalued even with its new product launch, which may temper enthusiasm following the rally and analyst target increases. Valuation analysis

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.